A detailed history of Gw&K Investment Management, LLC transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Gw&K Investment Management, LLC holds 37,761 shares of LGND stock, worth $4.21 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares
37,761
Previous 39,018 3.22%
Holding current value
$4.21 Million
Previous $3.29 Million 14.93%
% of portfolio
0.03%
Previous 0.03%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

SELL
$82.7 - $110.11 $103,953 - $138,408
-1,257 Reduced 3.22%
37,761 $3.78 Million
Q2 2024

Aug 12, 2024

SELL
$68.53 - $87.91 $51,191 - $65,668
-747 Reduced 1.88%
39,018 $3.29 Million
Q1 2024

May 08, 2024

SELL
$68.64 - $89.2 $1.07 Million - $1.39 Million
-15,570 Reduced 28.14%
39,765 $2.91 Million
Q4 2023

Feb 09, 2024

BUY
$49.57 - $72.63 $887,550 - $1.3 Million
17,905 Added 47.84%
55,335 $3.95 Million
Q3 2023

Nov 09, 2023

SELL
$58.86 - $72.67 $39,907 - $49,270
-678 Reduced 1.78%
37,430 $2.24 Million
Q2 2023

Aug 09, 2023

SELL
$69.53 - $79.33 $52,147 - $59,497
-750 Reduced 1.93%
38,108 $2.75 Million
Q1 2023

May 09, 2023

BUY
$65.67 - $77.08 $575,531 - $675,529
8,764 Added 29.12%
38,858 $2.86 Million
Q4 2022

Feb 10, 2023

SELL
$61.72 - $96.74 $19,133 - $29,989
-310 Reduced 1.02%
30,094 $2.01 Million
Q3 2022

Nov 09, 2022

SELL
$0.01 - $107.56 $32 - $350,215
-3,256 Reduced 9.67%
30,404 $2.62 Million
Q2 2022

Aug 09, 2022

SELL
$74.52 - $117.06 $90,392 - $141,993
-1,213 Reduced 3.48%
33,660 $3 Million
Q1 2022

May 09, 2022

BUY
$94.99 - $151.56 $889,391 - $1.42 Million
9,363 Added 36.7%
34,873 $3.92 Million
Q4 2021

Feb 11, 2022

BUY
$127.69 - $165.85 $3.26 Million - $4.23 Million
25,510 New
25,510 $3.94 Million

Others Institutions Holding LGND

About LIGAND PHARMACEUTICALS INC


  • Ticker LGND
  • Exchange OTC
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 16,882,800
  • Market Cap $1.88B
  • Description
  • Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...
More about LGND
Track This Portfolio

Track Gw&K Investment Management, LLC Portfolio

Follow Gw&K Investment Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Gw&K Investment Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Gw&K Investment Management, LLC with notifications on news.